<DOC>
	<DOCNO>NCT00280241</DOCNO>
	<brief_summary>This research study look effect ( good bad ) administer cyclophosphamide , fludarabine , rituximab . Clinical study combination therapy show high response rate use single drug , study evaluate side effect effectiveness combination .</brief_summary>
	<brief_title>Protocol Treatment Patients With Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>This study design expand highly successful combination rituximab , fludarabine cyclophosphamide patient previously untreated CLL . Responses range 90-98 % 55 % complete response report . However , bone marrow toxicity significant problem . This trial design reduce bone marrow toxicity decrease dos fludarabine cyclophosphamide , double dose rituximab maintenance dose rituximab two year , maintain even enhance efficacy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Diagnosis CD20 + CLL Peripheral blood absolute lymphocyte count &gt; 5,000/mm3 obtain within 2 week prior randomization . The lymphocytosis must consist small moderate size lymphocyte , ≤55 % ( great 55 % ) prolymphocytes , atypical lymphocyte , lymphoblasts morphologically . Phenotypically characterize CD20 + CLL define : 1 ) predominant population cell share Bcell antigens CD5 absence panTcelI marker ( CD3 , CD2 , etc . ) ; 2 ) Bcell express either kappa lambda light chain ; 3 ) surface immunoglobulin ( slg ) lowcell surface density expression . Splenomegaly , hepatomegaly lymphadenopathy require diagnosis CLL . Must require chemotherapy . Indications chemotherapy one following : One follow diseaserelated symptom Weight loss &gt; 10 % within previous 6 month . Fevers great 100.0° F 2 week without evidence infection . Night sweat without evidence infection . Evidence progressive marrow failure manifest development worsen anemia ( &lt; 10 g/dl ) and/or thrombocytopenia ( &lt; 100,000/mm3 ) . Massive ( i.e. , &gt; 6 cm leave costal margin ) progressive splenomegaly . Massive node cluster ( i.e. , &gt; 10 cm long diameter ) progressive adenopathy . Progressive lymphocytosis increase &gt; 50 % 2 month period , anticipate double time le 6 month . NOTE : Marked hypogammaglobulinemia development monoclonal protein absence criterion active disease sufficient protocol therapy . Serum creatinine &lt; 1.5 mg/dl . Bilirubin must &lt; 2 mg/dl , unless secondary tumor , obtain within 2 week prior randomization . Age &gt; 18 year . Not pregnant ( confirm serum pregnancy test female reproductive potential ) breast feeding , unknown effect drug child . ECOG performance status 02 . AST ATL &gt; 2x upper limit normal unless related CLL . Subject provide write informed consent . Exclusion criterion : Subjects autoimmune anemia thrombocytopenia eligible . No prior cytotoxic chemotherapy . Patients history steroid treatment CLL , autoimmune hemolytic anemia , autoimmune thrombocytopenia eligible . Subjects active infection require oral intravenous antibiotic resolution infection completion therapeutic antibiotic . Women childbearing potential sexually active male refuse use accept effective method contraception . Subjects second malignancy basal cell carcinoma skin situ carcinoma cervix eligible unless tumor treat curative intent least two year previously . History HIV CNS disease History psychiatric disorder would make difficult enroll follow patient trial . New York Heart Classification III IV heart disease . Hepatitis BsAg Hepatitis C positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Chronic</keyword>
	<keyword>Lymphocytic</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Rituximab</keyword>
</DOC>